The venture capital group's cooperative sub-fund investment in the company Weimai Medical's "Intravenous Radiofrequency Closure Generator" has been approved for market launch by the NMPA.

Recently, the venture capital group's cooperative sub-fund invested in Weimai Qingtong Medical Technology (Wuxi) Co., Ltd. (referred to as "Weimai Medical"), which has independently developed the EZClosure® intravascular radiofrequency closure generator that has officially been approved for market launch!

Lower limb venous insufficiency is a common vascular disease caused by abnormal venous valve function, abnormal venous wall structure, and venous hypertension. The incidence of this disease increases with age, and patients may experience a range of symptoms from cosmetic issues to clinical problems. Varicose veins are a common manifestation of venous insufficiency, with about 30% of adults in Western countries suffering from varicose veins. Reports indicate that the prevalence of varicose veins in China is 8.89%, with over 100 million affected individuals and an annual incidence rate of 0.5% to 3.0%. In recent years, clinical practice has validated several advantages of intravascular thermal ablation using radiofrequency technology, such as small incisions, mild pain, high venous occlusion rates, and short recovery times.

Weimai Medical has made radiofrequency ablation its primary research project for technology transformation, based on independent patents, forming a technical platform that includes electronic design, model simulation, biological design, production process design, and medical-engineering efficiency relationship algorithms, which are then productized into an intravascular radiofrequency closure system. The EZClosure system involves percutaneously inserting a catheter into the venous lumen to heat the venous wall, thereby achieving occlusion. It features a short learning curve, more comprehensive energy data, and a portable and lightweight product form.

Weimai Medical was established in July 2021, creating the country's first energy source ablation multi-disease EA-MDT treatment system. In June 2022, Weimai Medical received angel round investment from Nanjing Chuangyi Yuanjing Venture Capital Partnership (Limited Partnership) (referred to as "Chuangyi Yuanjing Fund"). The Chuangyi Yuanjing Fund is a cooperative sub-fund of the venture capital group, established in December 2020, with a fund size of 100 million yuan. The fund manager is Zhonghe Venture Capital, which participated in the investment of 44 million yuan from the Nanjing municipal science and technology innovation fund managed by the venture capital group. Zhonghe Venture Capital was originally the investment department of the former A-share listed company Xianghuoju Group, which successfully implemented investments, mergers, and acquisitions for over 20 industrial projects, creating significant economic value for its shareholders. Zhonghe Venture Capital was established in 2006 and gradually shifted towards VC and PE-type investments in the private equity field, currently managing three private equity investment funds, focusing on early-stage and growth-stage projects in high-tech or innovative models such as smart products, consumption upgrades, Internet+, private military industry, and biomedicine.

Source: Fund Department Wang Yanan

Reviewed by: Xue Yao

Published by: You Yi